# Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

> **NCT06975514** · PHASE3 · RECRUITING · sponsor: **Shanghai Haiyan Pharmaceutical Technology Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** YZJ-1139
- **DRUG:** Zolpidem

## Key facts

- **NCT ID:** NCT06975514
- **Lead sponsor:** Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2025-08
- **Final completion:** 2025-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975514, "Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06975514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*